About Us

Caribbean Biotech Labs (CBL) is a private Contract Research Organization (CRO) that strives to provide high-quality pre-clinical services to businesses in the Diagnostics, Pharmaceutical and Biotechnology industries. Featuring a State-of-the-Art Cell Culture Room where we combine our cell-line upstream and downstream development process to make sure our clients receive a well-branded nonclinical biologics with reliable product quality. Our GLP Immunology Lab is dedicated to developing and validate analytical methods with a unique Quality Management System (QMS) to ensure consistent results.

The CBL Scientific Team is highly experienced and result-oriented, with decades of experience in CLIA/CAP laboratory operations. Our customers can rest assured in our ability to not only deliver the highest quality in our services but also in our ability to understand and adapt to their needs with great flexibility.

Portfolio of Services

WORKING WITH CBL

Provides the opportunity to benefit from a myriad of attributes:

Relationship Building
More than an “order taker” we become a provider of value and a trusted partner, by engaging with our customers in a future-looking partnership to meet their research and development needs.
Flexibility
We foster a networked business model, with increasing collaboration and adaptability to our partner’s processes, ensuring quality and timely delivery. Our hallmark is “to become an extension of your laboratory”
Cost Advantage
Being located at a Free Zone allow us to benefit from operational costs savings that can be translated into better and more competitive prices.
Previous slide
Next slide

CBL is Contributing to Diagnosis of Rare Disease

Paraneoplastic Neurological Syndromes (PNS) are a group of conditions, normally known as a rare disease, that can affect part of the central and peripheral nervous system, the neuromuscular junction, and muscle, in patients with cancer. However, the neurological disorder develops before the cancer becomes clinically overt. 

Lambert-Eaton myasthenic syndrome (LEMS), subacute cerebellar ataxia and limbic encephalitis (LE) are some of the common manifestation of PNS, that are caused by autoimmune processes triggered by the cancer and directed against antigens common to the cancer and the nervous system. These Syndromes are normally severely disabling,

Due to their high specificity, it is agreed that the best way to diagnose a neurological disorder as paraneoplastic is to identify one of the well-characterized anti-onconeural protein antibodies in the patient’s serum.

Caribbean Biotech Labs (CBL) with decades of expertise on biologics purification and strong capabilities to both, prepare any kind of biologics and provide nonclinical end-to-end drug development services, offer a comprehensive panel of autoimmune disease antigens with proven track record for quality and sensitivity in Radioimmunoprecipitation assays. Lot to lot consistency of these native antigens shortens both assay development and validation process.

These autoimmune disease antigens are prepared under Good Laboratory Practices (GLP) regulations.

Native Autoimmune Disease Antigens

Antigen Clinical Association Source

Voltage-Gated Calcium Channels (VGCC)

Paraneoplastic Neurological Syndrome, (PNS), Lambert-Eaton Myasthenic Syndrome, (LEMS)

Rabbit Brain

Voltage-Gated Potassium Channels (VGKC)

Paraneoplastic Neurological Syndrome, (PNS), Autoimmune Encephalitis

Rabbit Brain

Ganglionic AcetylCholine Receptor (gAChR)

Paraneoplastic Neurological Syndrome (PNS), Autoimmune Autonomic Gangliopathy, (AAG)

Human Neuroblastoma Cell Line, (IMR-32)
Scroll to Top